# Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

> **NCT02784171** · PHASE2,PHASE3 · COMPLETED · sponsor: **Canadian Cancer Trials Group** · enrollment: 520 (actual)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02784171
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-11
- **Primary completion:** 2024-10-11
- **Final completion:** 2024-10-11
- **Target enrollment:** 520 (ACTUAL)
- **Last updated:** 2024-12-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02784171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02784171, "Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02784171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*